Clinical trials in multiple sclerosis - The importance of the outcome measure

被引：0
|
作者：
Zajicek, J
Thompson, A
Hobart, J
机构：
[1] Peninsula Med Sch, Plymouth, Devon, England
[2] Derriford Hosp, Plymouth PL6 8DH, Devon, England
[3] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2004年 / 75卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
013
引用
收藏
页码：1215 / 1215
页数：1
相关论文
共 50 条
  • [31] Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
    Liu, C
    Po, ALW
    Blumhardt, LD
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (06): : 726 - 729
  • [32] Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis
    Cawley, Niamh
    Tur, Carmen
    Prados, Ferran
    Plantone, Domenico
    Kearney, Hugh
    Abdel-Aziz, Khaled
    Ourselin, Sebastian
    Wheeler-Kingshott, Claudia A. M. Gandini
    Miller, David H.
    Thompson, Alan J.
    Ciccarelli, Olga
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (07) : 932 - 941
  • [33] Spinal cord atrophy as a primary outcome measure in primary progressive multiple sclerosis neuroprotective trials
    Cawley, N.
    Abdel-Aziz, K.
    Schneider, T.
    Altmann, D.
    Wheeler-Kingshott, C. A. M.
    Miller, D. H.
    Thompson, A. J.
    Ciccarelli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 189 - 190
  • [34] Clinical trials in multiple sclerosis: milestones
    Zhang, Yinan
    Salter, Amber
    Cutter, Gary
    Stuve, Olaf
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [35] Methodology of clinical trials in multiple sclerosis
    Mitsikostas, D. D.
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 5) : S362 - S364
  • [36] Methodology of clinical trials in multiple sclerosis
    D. D. Mitsikostas
    Neurological Sciences, 2006, 27 : s362 - s364
  • [37] Evolution of clinical trials in multiple sclerosis
    Zhang, Yinan
    Salter, Amber
    Wallstroem, Erik
    Cutter, Gary
    Stueve, Olaf
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12
  • [38] Organ dysfunction as an outcome measure in clinical trials
    Marshall, JC
    EUROPEAN JOURNAL OF SURGERY, 1999, 163 : 62 - 67
  • [39] Meta-analysis of Phase 2 and 3 Fampridine Trials in Multiple Sclerosis: efficacy assessment and validation of clinical meaningfulness of outcome measure
    Goodman, A. D.
    Brown, T. R.
    Cohen, J. A.
    Krupp, L.
    Schapiro, R.
    Schwid, S. R.
    Cohen, R.
    Marinucci, L.
    Blight, A.
    MULTIPLE SCLEROSIS, 2007, 13 : S33 - S33
  • [40] The timed 25-foot walk as an outcome measure for clinical trials in multiple sclerosis: further evidence that a 20% change is clinically meaningful
    Hobart, J.
    Blight, A.
    Lynn, F.
    Putzki, N.
    JOURNAL OF NEUROLOGY, 2011, 258 : 150 - 150
12345